This episode of The Motley Fool's Market Checkup is dedicated to the world's largest pure play biotech stock, Gilead Sciences . Market Checkup gives a full examination of Gilead's second-quarter results, takes a closer look at the company's current product portfolio and analyzes the future drugs that have investors excited about the stock's future.
In this video, health-care analysts David Williamson and Max Macaluso drill down on Gilead's strong drug development pipeline. Watch and find out why investors should be excited about Gilead's diversification into oncology products and which blood cancer drug is poised to become a blockbuster despite fierce potential competition from Johnson & Johnson.
Rising health care costs continue to be a hotly debated topic, and even legendary investor Warren Buffett called this trend "the tapeworm that's eating at American competitiveness." To learn more about what's happening to the health care system -- and how to potentially profit from this trend -- click here for free, immediate access.
Follow David on Twitter: @MotleyDavid.
The article 1 Biotech Pipeline Packed with Potential originally appeared on Fool.com.
David Williamson owns shares of Johnson & Johnson and Novartis. Follow David on Twitter: @MotleyDavid. Max Macaluso, Ph.D. owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.